Bristol-Myers Squibb | BMY

Stock Price
47.14
Daily Change
0.45 0.96%
Monthly
5.18%
Yearly
-3.28%
Q3 Forecast
46.75

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Abbott 132.94 0.13 0.10% 16.68% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novo Nordisk A/S 350.00 -10.50 -2.91% -60.30% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05

Indexes Price Day Year Date
US500 6481 -20.59 -0.32% 19.84% Sep/05

Bristol-Myers Squibb traded at $47.14 this Friday September 5th, increasing $0.45 or 0.96 percent since the previous trading session. Looking back, over the last four weeks, Bristol-Myers Squibb gained 5.18 percent. Over the last 12 months, its price fell by 3.28 percent. Looking ahead, we forecast Bristol-Myers Squibb to be priced at 46.75 by the end of this quarter and at 45.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.